These results indicate that STZY largely exerts its anti-RA therapeutic effects through regulating signaling pathways such as PI3K/AKT, NF-κB, and HIF-1, via its effect on IL-1α, IL-1β, IL-2, IL-6, and IL-10. The gene discussed is IL1A; the disease is rheumatoid arthritis.